FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808128519> ?p ?o ?g. }

• W2808128519 abstract "Background LBEC0101 is a newly developed biosimilar of etanercept (ETN). As rheumatoid arthritis (RA) treatment is a long-standing process in the clinical practice, the long-term safety and efficacy of anti-TNF inhibitors have been studied and reported.1 Clinical studies have been conducted to evaluate the efficacy and safety of biosimilar after switching from their originator drug.2 Objectives To evaluate the long-term efficacy, safety, and immunogenicity of switching from the ETN reference product (RP) to LBEC0101 or continuing LBEC0101 in patients with RA. Methods This multicenter, single-arm, open-label extension study enrolled patients with RA who had completed the 52 week treatment period of the randomised, double-blind, parallel-group, Phase III study for LBEC0101 (NCT02357069). Patients who were deemed requiring continuous treatment for RA upon the investigator’s discretion and agreed to participate in this study were allowed for participation. All patients received LBEC0101 50 mg/ml once a week for 48 weeks with the stable dose of methotrexate regardless of the randomization group in the Phase III study. Efficacy, safety and immunogenicity were assessed up to Week 100. Data were analysed for patients who continued to receive LBEC0101 for 100 weeks (maintenance group) and for those who had received ETN-RP for 52 weeks and then switched to LBEC0101 for 48 weeks (switch group). Results A total of 148 patients were enrolled in this study; 70 patients continued to receive LBEC0101 and 78 patients switched to receive LBEC0101 from ETN-RP. DAS28-ESR score in the full analysis set were maintained in both groups from week 52 through week 100 (from 3.068 to 3.103 in maintenance group vs. from 3.161 to 3.079 in switch group). Response rates at week 100 for maintenance and switch groups, respectively, were 79.7% vs. 83.3% for ACR20, 65.2% vs. 66.7% for ACR50% and 44.9% vs. 42.3% for ACR70. The incidences of adverse events were comparable between the groups (70.0% for maintenance group and 70.5% for switch group, respectively). The proportion of patients who newly developed antidrug antibodies was similar between the groups (1.4% for maintenance group and 1.3% for switch group, respectively). Conclusions The efficacy and safety of LBEC0101 were comparable in both maintenance and switch groups. The efficacy of LBEC0101 was well sustained over 100 weeks. References [1] Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken)2011;63:373–82. [2] Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis2017 [Epub ahead of print]. Acknowledgements HanJoo Baek, HoonSuk Cha, JungYoon Choe, ChanBum Choi, InAh Choi, SeungJae Hong, JinWuk Hur, GeunTae Kim, HyunAh Kim, Jinseok Kim, Jisoo Lee, SangHeon Lee, SangIl Lee, SeungGeun Lee, ShinSeok Lee, YunJong Lee, JunKi Min, KyungSu Park, SungHwan Park, Won Park, YongBeom Park, DongHyuk Sheen, SeungCheol Shim, KichulShin, ChangHee Suh, HyungIn Yang, Bin Yoo and WanHee Yoo. Disclosure of Interest Y. W. Song: None declared, H. Matsuno Consultant for: Mochida Pharmaceutical Co., Ltd., AYUMI Pharmaceutical Corporation, Nichi-Iko Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., M.-C. Park: None declared, M. Tomomitsu Employee of: Mochida Pharmaceutical Co., Ltd., S. Shin Employee of: LG Chem, Ltd., J. Lee Employee of: LG Chem, Ltd." @default.
• W2808128519 created "2018-06-21" @default.
• W2808128519 creator A5004952398 @default.
• W2808128519 creator A5008053939 @default.
• W2808128519 creator A5049316776 @default.
• W2808128519 creator A5052081691 @default.
• W2808128519 creator A5054304061 @default.
• W2808128519 creator A5066282735 @default.
• W2808128519 date "2018-06-01" @default.
• W2808128519 modified "2023-09-28" @default.
• W2808128519 title "AB0456 Efficacy and safety of switching from etanercept reference product to lbec0101 (ETANERCEPT BIOSIMILAR) compared with continuing lbec0101 in patients with rheumatoid arthritis" @default.
• W2808128519 doi "https://doi.org/10.1136/annrheumdis-2018-eular.1316" @default.
• W2808128519 hasPublicationYear "2018" @default.
• W2808128519 type Work @default.
• W2808128519 sameAs 2808128519 @default.
• W2808128519 citedByCount "1" @default.
• W2808128519 countsByYear W28081285192020 @default.
• W2808128519 crossrefType "proceedings-article" @default.
• W2808128519 hasAuthorship W2808128519A5004952398 @default.
• W2808128519 hasAuthorship W2808128519A5008053939 @default.
• W2808128519 hasAuthorship W2808128519A5049316776 @default.
• W2808128519 hasAuthorship W2808128519A5052081691 @default.
• W2808128519 hasAuthorship W2808128519A5054304061 @default.
• W2808128519 hasAuthorship W2808128519A5066282735 @default.
• W2808128519 hasBestOaLocation W28081285191 @default.
• W2808128519 hasConcept C126322002 @default.
• W2808128519 hasConcept C2777226972 @default.
• W2808128519 hasConcept C2777575956 @default.
• W2808128519 hasConcept C2909063479 @default.
• W2808128519 hasConcept C59491497 @default.
• W2808128519 hasConcept C71924100 @default.
• W2808128519 hasConceptScore W2808128519C126322002 @default.
• W2808128519 hasConceptScore W2808128519C2777226972 @default.
• W2808128519 hasConceptScore W2808128519C2777575956 @default.
• W2808128519 hasConceptScore W2808128519C2909063479 @default.
• W2808128519 hasConceptScore W2808128519C59491497 @default.
• W2808128519 hasConceptScore W2808128519C71924100 @default.
• W2808128519 hasLocation W28081285191 @default.
• W2808128519 hasOpenAccess W2808128519 @default.
• W2808128519 hasPrimaryLocation W28081285191 @default.
• W2808128519 hasRelatedWork W1993992685 @default.
• W2808128519 hasRelatedWork W2023378412 @default.
• W2808128519 hasRelatedWork W2617521628 @default.
• W2808128519 hasRelatedWork W2738087986 @default.
• W2808128519 hasRelatedWork W2764032337 @default.
• W2808128519 hasRelatedWork W2801418762 @default.
• W2808128519 hasRelatedWork W4233599538 @default.
• W2808128519 hasRelatedWork W4235626084 @default.
• W2808128519 hasRelatedWork W4243348309 @default.
• W2808128519 hasRelatedWork W2181999114 @default.
• W2808128519 isParatext "false" @default.
• W2808128519 isRetracted "false" @default.
• W2808128519 magId "2808128519" @default.
• W2808128519 workType "article" @default.